| P50 | author | Bryant W Megna | Q59974872 |
| P2093 | author name string | Mary S Hayney | |
| | Sumona Saha | |
| | Arnold Wald | |
| | Mark Reichelderfer | |
| | Freddy Caldera | |
| | Dana Ley | |
| | Sue McCrone | |
| | Christine A Garmoe | |
| P2860 | cites work | California pertussis epidemic, 2010. | Q46520794 |
| | Immunity to tetanus and diphtheria in the UK in 2009. | Q50121535 |
| | Recommended Immunization Schedule for Adults Aged 19 Years or Older, United States, 2017 | Q64124783 |
| | Antibody responses to Bordetella pertussis antigens and clinical correlations in elderly community residents | Q64449676 |
| | Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis | Q64449889 |
| | Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP) | Q73199891 |
| | More than 20 years after re-emerging in the 1990s, diphtheria remains a public health problem in Latvia | Q33553195 |
| | Normal response to vaccines in inflammatory bowel disease patients treated with thiopurines | Q34173362 |
| | Safety and immunogenicity of tetanus-diphtheria-acellular pertussis vaccine administered to children 10 or 11 years of age. | Q34592959 |
| | Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States | Q34655381 |
| | Durability of Vaccine-Induced Immunity Against Tetanus and Diphtheria Toxins: A Cross-sectional Analysis | Q36783207 |
| | Effectiveness of pertussis vaccination and duration of immunity. | Q37382056 |
| | Correlates of protection induced by vaccination | Q37750121 |
| | Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. | Q38194708 |
| | Immunogenicity of Pertussis Booster Vaccination in Children and Adolescents with Inflammatory Bowel Disease: A Controlled Study. | Q38844359 |
| | ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease | Q39029698 |
| | Many Inflammatory Bowel Disease Patients Are Not Immune to Measles or Pertussis. | Q40564307 |
| | Combined Immunosuppression Impairs Immunogenicity to Tetanus and Pertussis Vaccination Among Patients with Inflammatory Bowel Disease | Q41222715 |
| | Tdap vaccine effectiveness in adolescents during the 2012 Washington State pertussis epidemic | Q41259190 |
| | Immunogenicity of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine compared to standard-dose diphtheria, tetanus, acellular pertussis when used as a pre-school booster in UK chi | Q41593711 |
| | A cross-sectional study of tetanus and diphtheria antibody concentrations post vaccination among lung transplant patients compared with healthy individuals | Q41757754 |
| | Immunogenicity and safety of one dose of diphtheria, tetanus, acellular pertussis and poliomyelitis vaccine (Repevax®) followed by two doses of diphtheria, tetanus and poliomyelitis vaccine (Revaxis®) in adults aged ≥ 40 years not receiving a diphth | Q42217195 |
| | Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease | Q42609131 |
| | Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix(®)): results of two randomized trials | Q44939855 |
| | American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease | Q46229958 |
| P433 | issue | 6 | |
| P921 | main subject | inflammatory bowel diseases | Q917447 |
| P304 | page(s) | 1532-1540 | |
| P577 | publication date | 2018-03-29 | |
| P1433 | published in | Digestive Diseases and Sciences | Q15716711 |
| P1476 | title | Lower Sustained Diphtheria and Pertussis Antibody Concentrations in Inflammatory Bowel Disease Patients | |
| P478 | volume | 63 | |